Cushing’s Syndrome: Development of Highly Potent and Selective CYP11B1 Inhibitors of the (Pyridylmethyl)pyridine Type-Reference-Cited by-同舟云学术

Cushing’s Syndrome: Development of Highly Potent and Selective CYP11B1 Inhibitors of the (Pyridylmethyl)pyridine Type

Published:2013-07-19 Issue:15 Volume:56 Page:6022-6032
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Emmerich Juliette¹,Hu Qingzhong¹,Hanke Nina²,Hartmann Rolf W.¹

Affiliation:

1. Pharmaceutical and Medicinal Chemistry, Saarland University, and Department of Drug Design and Optimization, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Campus C2-3, 66123 Saarbrücken, Germany

2. Elexopharm GmbH, Campus A1, 66123 Saarbrücken, Germany

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm400240r

Reference29 articles.

1. Medical management of Cushing’s disease: what is the future?

2. Pharmacological management of Cushing's syndrome: an update

3. Obesity and corticosteroids: 11β-Hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease

4. Modifiers of steroid-hormone metabolism: a review of their chemistry, biochemistry and clinical applications

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Electrochemical γ-Selective Deuteration of Pyridines;Organic Letters;2024-05-16

2. Drug development and potential targets for Cushing's syndrome;European Journal of Medicinal Chemistry;2024-04

3. Cytochrome P450 enzymes as drug targets in human disease;Drug Metabolism and Disposition;2023-10-04

4. Virtual screening and biological evaluation to identify pharmaceuticals potentially causing hypertension and hypokalemia by inhibiting steroid 11β-hydroxylase;Toxicology and Applied Pharmacology;2023-09

5. Lipid Profiling Reveals Lipidomic Signatures of Weight Loss Interventions;Nutrients;2023-04-06